Abstract: A compound for use especially as an antiviral drug, mainly containing salts of heteropolyanions consisting of a tungstoantimonate (III) vanadium-mixed metal oxide or related salts represented by formula [(XW9O33)2V3O3]P−, where p is a positive number between 9 and 12 and X is Sb, P. As or Bi and especially Sb. An antiviral drug having a broad spectrum of antiviral activity, high potent efficacy and low toxicity is provided.

Abstract: A protectant composition comprising vernix for a skin curative and skin protectant effect and a method of using the composition. A natural or synthetic vernix is dispersed in an effect amount and is applied to a surface. The method may be used to repel a naturally occurring agent such as water, or a synthetic agent to which exposure may occur, for example, in an occupational setting.

Abstract: The present invention is directed to a low VOC, non-aerosol, polyacrylic acid containing hair cosmetic compositions which contain stabilized starches, particularly those derivatized by alkylene oxides, about 01.-0.0% polyacrylic acid, up to about 15% solvent, and water. The derivatized starch may be hydrolyzed, particularly enzymatically hydrolyzed by at least one endo-enzyme. In addition, the starch may be cationically modified with a low degree of substitution. Use of such starches is novel and advantageous in that they are compatible with polyacrylic acid, providing a clear, solution with a stable viscosity. Further, the resultant composition provides a clear film which is not tacky, good stiffness, and improved humidity resistance.

Abstract: A mating disruption method for the control of insect pests comprises releasing a sex pheromone in a field wherein an adsorption of the sex pheromone to a soil in the field is decreased.

Abstract: Cinnamic acid and derivatives thereof are well suited for promoting desquamation and/or stimulating epidermal renewal and/or combating intrinsic/extrinsic aging of the skin of a human subject in need of such treatment, by topically applying thereto, for such period of time as required to elicit the desired response, a cosmetically/therapeutically effective amount of cinnamic acid and/or of at least one derivative thereof.

Abstract: Emulsifier-free cosmetic or dermatological preparations, which are finely dispersed systems of the oil-in-water type, comprising 1. an oil phase, 2. an aqueous phase and 3. one or more types of micronized, inorganic pigments which a) have an average particle size of less than 200 nm, and whose particles b) have both hydrophilic and lipophilic properties, i.e. have an amphiphilic character, and thus position themselves at the water/oil interface, and which c) are selected from the group consisting of metal oxides, which d) are optionally coated on the surface and also optionally comprising further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients.

Abstract: Compositions including zinc compounds and select amino acids in a carrier base, and methods of skin treatment with such compositions, are described. The compositions are useful for healing skin and minimizing the irritation incurred from contact with the zinc compound without loss of zinc availability during absorption into the integument.

Abstract: A method for treating a patient suffering from a renal failure progressed to a stage at which an initiation of a dialysis therapy is required, comprising combining a peritoneal dialysis and an administration of a spherical carbon, is disclosed.

Abstract: A cosmetic product and the like, including a deodorant, comprising a dicarboxylic acid and sodium bicarbonate preferably dihydroxybutanedioic acid and sodium bicarbonate and most preferably comprising cream of tarter and sodium bicarbonate. A mixture of sodium bicarbonate, cream of tarter and water forms a paste which hardens into a solid over a period of a few hours. The mixture provides a solid material which is highly stable. It does not dissolve quickly and does not effervesce, but instead remains essentially stable and retains it's solid form.

Abstract: The invention relates to a transdermal therapeutic system (TTS) containing desoxypeganine (1,2,3,9-Tetrahydropyrrolo[2,1-b]quinazoline) as the active component, wherein the TSS includes a back layer impermeable to desoxypeganine and an adhesive reservoir layer that contains 10-80 weight percent polymeric material, 0.1-30 weight percent desoxypeganine and/or the pharmaceutically acceptable salts thereof and optionally a softening agent in proportions of 0.1-30 weight percent.

Abstract: An adsorbent for removing a chemokine except interleukin-8 in body fluid, which comprises a solid material having an anionic functional group, a method for efficiently removing a chemokine except interleukin-8 in body fluid, which comprises by bringing the above adsorbent into contact with body fluid containing the chemokine and an adsorber for removing a chemokine except for interleukin-8 using the above adsorbent.

Abstract: Cosmetic product systems comprise a transfer resistant, flexible film forming cosmetic product having a solubility parameter on the Hildebrand scale of less than or equal to 8.5 (calories/cm3)½, and a second composition comprising an oil having a C log P value greater than or equal to 13. The oil is selected from the group consisting of polyol fatty acid polyesters, triglycerides, glycerin/diethylene glycol/adipate cross polymers and mixtures thereof.

Abstract: The present invention is concerned with a biomedical molding comprising a non-biodegradable biocompatible organic polymer comprising attached to its surface radicals of formula wherein the variables are as defined in the claims. The biomedical moldings of the invention are radiation sensitive and may be used, for example, as intraocular lens in ophthalmic surgery.

Abstract: The present invention is directed to methods of using pro-NAD agents capable of enhancing the dermal and epidermal skin cell NAD content. These pro-NAD agents may be administered topically, orally, or parenterally to enhance DNA repair and other protective responses to DNA damage. The invention further relates to pharmaceutical compositions comprising pro-NAD agents that effectively elevate intracellular NAD content. Finally, the invention relates to the method of using the pro-NAD agents to treat disorders such as sunburn and other skin deterioration that results from DNA damage in skin cells.

Abstract: Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of an active agent and a mucosal adhesion enhancer; wherein the active agent is encapsulated within a polymer which is chemically or physically distinct from the hydocolloid; wherein the mucosal adhesion enhancer is a starch graft copolymer; wherein the film exhibits a dry tack value of less than 3.5 g, a wet tack of greater than 35 g, a gelation temperature that is greater than 70° C. for a 2% polymer solution, a dry film thickness of less than 20 mil, a water content of 0.5 to 10%, a tensile strength greater than 1500 psi, a modulus in the range of 35,000 to 300,000 psi, a % elongation of less than 20%, a tear probagation resistance of 0.001 to 1 N, and a dissolution time in the range of 1 to 600 seconds upon application to an oral mucosal surface.

Abstract: Hair styling compositions that comprise at least one adhesive particle, optionally in a cosmetically acceptable carrier, wherein said at least one adhesive particle comprises at least one substrate and an at least partial coating, wherein said at least partial coating comprises at least one adhesive, wherein the at least one substrate and the at least partial coating are not the same, and wherein the at least one adhesive particle has a mean length greater than 1 micron. The present invention also relates to methods of providing a holding and/or reshapable effect to the hair using the compositions of the invention and methods of manufacturing of said compositions.

Abstract: The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.

Abstract: The object of the present invention is to provide a pharmaceutical composition optimized for the administration of a drug, particularly a drug which is only sparingly soluble in water, by way of inhalation. The present invention is a fat emulsion for inhalational administration, or a lyophilized composition thereof, which is an o/w fat emulsion comprising fat emulsion particles essentially composed of an oil component, an emulsifying agent and a drug as dispersed in water, characterized in that the average particle diameter of said fat emulsion particles lies within the range of 5˜100 nm. With the aid of a suitable inhaler, the inhalant of the invention readily yields a mist of aerosol particles fine enough to reach the alveolus; the inhalant is well amenable to size control of the aerosol particles.

Abstract: Controlled-release formulation having such a portion that the core and a drug release layer each of which has been formulated to effect rapid or gradual release of at least one drug the release of which is to be controlled is covered either partly or entirely with a release control layer that is produced by adding pharmaceutically acceptable additives to at least one base selected from among fumaric acid, DL-tryptophan and L-tyrosine and which is substantially free from the drugs the release of which is to be controlled.

Abstract: The present invention provides a nanoemulsion, that includes: an oily phase dispersed in an aqueous phase; and at least one glycerol fatty ester surfactant which is solid at a temperature of less than or equal to 45° C.; wherein the oily phase includes oil globules having a number-average size of less than 100 nm; wherein the oily phase includes at least one oil having a molecular weight of greater than 400; and wherein a weight ratio of the oily phase to the surfactant ranges from 2 to 10. The invention also provides a process for making the nanoemulsion and methods for its use. Ideally, the emulsion is transparent and stable on storage. It can ideally contain large amounts of oil while retaining good transparency and good cosmetic properties. The nanoemulsion is particularly useful in the cosmetics and dermatological fields, in particular for moisturizing the skin and/or mucous membranes, as well as for treating the hair, and, in the ophthalmological field, as an eye lotion for treating the eyes.